PrepCatPrepCat
← Back to Section
Science8/30/2026

PRIP Scheme's Second Call: India's ₹5,000-Crore Push for Pharma and MedTech Innovation

The Department of Pharmaceuticals has opened the second call for applications under the Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), a ₹5,000 crore initiative meant to shift India's pharma industry from cost-based competitiveness to innovation-led growth. For Prelims, it is a textbook case of a Production-Linked-Incentive-adjacent scheme built around Technology Readiness Levels (TRLs) rather than manufacturing output, making it a favourite trap for students who lump every industry scheme into the PLI basket.

📌 Revision Pointers

  • Scheme name — Promotion of Research and Innovation in Pharma MedTech Sector (PRIP).
  • Nodal body — Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
  • Total outlay — ₹5,000 crore for the period 2023-24 to 2027-28.
  • Split — around ₹700 crore for Centres of Excellence at NIPERs; around ₹4,250 crore for direct R&D funding.
  • Funding cap — up to ₹100 crore per project, capped at 35 percent of approved project cost, rest co-funded by the applicant.
  • Six priority areas — new chemical/biological/phytochemical entities, complex generics and biosimilars, precision medicine, medical devices, orphan drugs, and AMR drug development.

Core Context

India is the world's largest supplier of generic medicines by volume, but its pharmaceutical growth story has largely been built on manufacturing scale rather than original research. Domestic spending on pharmaceutical R&D remains a fraction of what innovator nations invest, and Indian companies have historically preferred to replicate proven molecules rather than discover new ones. To correct this, the Union Cabinet approved the PRIP Scheme in 2023 for a five-year period, run by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers. Its stated goal is to transform the country's Pharma MedTech sector into a genuine innovation powerhouse by de-risking early and mid-stage research, an area private capital in India has traditionally avoided because returns are distant and uncertain.

The scheme's ₹5,000 crore outlay is split into two broad streams: about ₹700 crore is earmarked to set up Centres of Excellence at the National Institutes of Pharmaceutical Education and Research (NIPERs), building long-term research infrastructure, while the remaining roughly ₹4,250 crore directly funds R&D projects. Funding is organised into tiers by the size and maturity of the applicant and project, so a large company with an established R&D budget is treated differently from a startup working on an early-stage idea, and support scales with how far along a technology already is.

Latest Developments

On 28 August 2026, the Department of Pharmaceuticals announced the second call for applications under PRIP, with the application window set to open by mid-September 2026. Support is offered across two broad project tracks: an early-stage track for startups and MSMEs working to advance a technology from Technology Readiness Level (TRL) 1-3 to a higher level, and a later-stage track for industry, startups and MSMEs working at TRL 4-6 who need funding to push a proven concept closer to market readiness. Financial assistance can go up to ₹100 crore per project, capped at 35 percent of the approved project cost, with the applicant expected to co-fund the rest. The ministry has clarified that projects funded or rejected in the first round cannot be resubmitted, pushing applicants to bring genuinely new research proposals in this cycle.

The scheme identifies six priority research areas: new chemical, biological or phytochemical entities; complex generics and biosimilars; precision medicine; medical devices; orphan drugs; and drug development for Antimicrobial Resistance (AMR), a category of direct relevance to India's public health burden.

UPSC Prelims Angle

  • PRIP is administered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, not the Ministry of Health and Family Welfare, a distinction examiners like to test.
  • The scheme uses Technology Readiness Level (TRL), a globally used scale from TRL 1 (basic research) to TRL 9 (fully proven technology), to decide which funding track and cap applies to a project.
  • AMR (Antimicrobial Resistance) featuring as a named priority area links this scheme to the broader One Health approach and India's National Action Plan on AMR, a recurring Prelims and Mains theme.

💭 Conclusion

PRIP sits at the intersection of two GS themes aspirants often study in isolation: government schemes for economic development, and science and technology policy. It is worth remembering not just as one more acronym in the pharma space, but as an example of how the government is trying to use targeted, TRL-linked funding to fix a structural gap, India's weak private R&D spending, rather than simply offering production incentives. Keep an eye on how this scheme's outcomes evolve over its five-year window; it is exactly the kind of policy story that resurfaces in both Prelims facts and Mains answers on self-reliance in healthcare. Stay consistent with such deep dives and the connections across schemes will start making themselves.